OBJECTIVES: To report the clinical outcomes of the VictoTM (Promedon, Cordoba, Argentina) adjustable artificial urinary sphincter (AUS) implantation in a cohort of patients with severe urinary incontinence (UI) after prostate surgery. PATIENTS AND METHODS: This study enrolled patients with UI following prostate surgery who underwent a Victo implantation between May 2018 and December 2023. Patients were prospectively evaluated at baseline, and at 3 and 12 months after device activation, and thereafter annually. The 24-h pad-weight test (24hPWT) was used to assess severity of UI, while the Patient Global Impression of Improvement (PGI-I) and patient satisfaction according to a Likert scale were used to measure patient-reported outcomes. RESULTS: A total of 96 patients with a median (interquartile range [IQR]) age of 68 (65-72) years were included in the final analysis. The median (IQR) follow-up was 3 (1-4) years. In all, 10 patients completed the 5-year follow-up. After the treatment, we observed a significant reduction in 24hPWT by the median of 83% (P < 0.001) at 3 months and by a median of 79% (P < 0.001) at 3 years. According to the PGI-I, a total of 87%, 92%, 87%, 81%, 83%, and 50% (five of 10) of patients rated their condition/incontinence as 'very much improved', 'much improved' or 'little improved' at 3 months, 1-, 2-, 3-, 4-, and 5-year follow-up visits, respectively. The proportion of patients, who were 'very satisfied' or 'satisfied' with the treatment outcome was 79%, 80%, 75%, 69%, 80%, and 60% (six of 10) at 3 months, 1-, 2-, 3-, 4-, and 5-years, respectively. There were a total of 13 (14%) device failures during the follow-up period. CONCLUSION: In conclusion, our data suggest that Victo AUS significantly reduces the severity of UI after prostate surgery and provides a reasonably high patient-reported satisfaction with treatment outcomes at mid-term follow-up.

• MeSH
• inkontinence moči * chirurgie   terapie   MeSH
• lidé středního věku MeSH
• lidé MeSH
• pooperační komplikace MeSH
• prospektivní studie MeSH
• prostatektomie * škodlivé účinky   MeSH
• senioři MeSH
• spokojenost pacientů MeSH
• umělý močový svěrač * MeSH
• výsledek terapie MeSH
• Check Tag
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• senioři MeSH
• Publikační typ
• časopisecké články MeSH

CONTEXT: Symptomatic lymphocele (sLC) occurs at a frequency of 2-10% after robot-assisted radical prostatectomy (RARP) with pelvic lymph node dissection (PLND). Construction of bilateral peritoneal interposition flaps (PIFs) subsequent to completion of RARP + PLND has been introduced to reduce the risk of lymphocele, and was initially evaluated on the basis of retrospective studies. OBJECTIVE: To conduct a systematic review and meta-analysis of only randomized controlled trials (RCTs) evaluating the impact of PIF on the rate of sLC (primary endpoint) and of overall lymphocele (oLC) and Clavien-Dindo grade ≥3 complications (secondary endpoints) to provide the best available evidence. EVIDENCE ACQUISITION: In accordance with the Preferred Reporting Items for Meta-Analyses statement for observational studies in epidemiology, a systematic literature search using the MEDLINE (PubMed), Cochrane Central Register of Controlled Trials (CENTRAL), and EMBASE databases up to February 3, 2023 was performed to identify RCTs. The risk of bias (RoB) was assessed using the revised Cochrane RoB tool for randomized trials. Meta-analysis used random-effect models to examine the impact of PIF on the primary and secondary endpoints. EVIDENCE SYNTHESIS: Four RCTs comparing outcomes for patients undergoing RARP + PLND with or without PIF were identified: PIANOFORTE, PerFix, ProLy, and PLUS. PIF was associated with odds ratios of 0.46 (95% confidence interval [CI] 0.23-0.93) for sLC, 0.51 (95% CI 0.38-0.68) for oLC, and 0.41 (95% CI 0.21-0.83) for Clavien-Dindo grade ≥3 complications. Functional impairment resulting from PIF construction was not observed. Heterogeneity was low to moderate, and RoB was low. CONCLUSIONS: PIF should be performed in patients undergoing RARP and simultaneous PLND to prevent or reduce postoperative sLC. PATIENT SUMMARY: A significant proportion of patients undergoing prostate cancer surgery have regional lymph nodes removed. This part of the surgery is associated with a risk of postoperative lymph collections (lymphocele). The risk of lymphocele can be halved via a complication-free surgical modification called a peritoneal interposition flap.

• MeSH
• lidé MeSH
• lymfadenektomie škodlivé účinky   metody   MeSH
• lymfokela * epidemiologie   etiologie   chirurgie   MeSH
• nádory prostaty * patologie   MeSH
• prostatektomie škodlivé účinky   metody   MeSH
• randomizované kontrolované studie jako téma MeSH
• robotika * MeSH
• Check Tag
• lidé MeSH
• mužské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• metaanalýza MeSH
• přehledy MeSH
• systematický přehled MeSH

BACKGROUND: Symptomatic lymphoceles present the most common complication of robot-assisted radical prostatectomy (RARP) with extended pelvic lymph node dissection (ePLND). No surgical technique has so far shown success in reducing the incidence rate, but several retrospective studies have shown the beneficial effect of the fixation of the peritoneum. OBJECTIVE: To introduce a modification in the technique of fixing the peritoneum to the pubic bone and to confirm whether this intervention reduces the incidence of lymphoceles. DESIGN, SETTING, AND PARTICIPANTS: A prospective randomized (1:1) single-center one-sided blind study was conducted in patients with localized prostate cancer (cT1-2cN0M0) indicated for RARP with ePLND operated between December 2019 and June 2021. In the intervention group, the free flap of the peritoneum was fixed to the pubic bone. In the control group, the peritoneal flap was left free without fixation. SURGICAL PROCEDURE: In the intervention group, the free flap of the peritoneum was fixed to the pubic bone (PerFix) so that lateral holes were left, allowing drainage of lymph from the pelvis into the abdominal cavity, where it would be resorbed. The iliac vessels and obturator fossa remained uncovered by the peritoneum and the bladder. MEASUREMENTS: The primary objective was to evaluate the frequency of symptomatic lymphoceles during follow-up. The secondary endpoints were the radiological presence of lymphoceles on computed tomography of the pelvis carried out 6 wk after surgery, the volume of the lymphoceles, and the degree of severe (Clavien-Dindo ≥3) complications. RESULTS AND LIMITATIONS: Of the 260 randomized patients, 245 were evaluated in the final analysis-123 in the intervention and 122 in the control group. The median follow-up was 595 d. There were no differences between the groups regarding clinical and pathological variables. The median of 17 nodes removed was the same in both groups (p = 0.961). Symptomatic lymphoceles occurred in 17 patients (6.9%), while in the intervention group these were found in three (2.4%) versus 14 (11.5%) in the control group (p = 0.011). The number of radiologically detected asymptomatic lymphoceles did not differ (p = 0.095). There was no significant difference in lymphocele volume between the two groups (p = 0.118). The rate of serious complications (Clavien 3a and 3b) was 4.8% in the intervention group and 9.1% in the control group (p = 0.587). A multivariate logistic regression model of symptomatic lymphocele occurrence was created with significant factors: body mass index (odds ratio [OR] = 1.1, 95% confidence interval [CI] = [1.03, 1.26], p = 0.012) and intervention (OR = 4.6, 95% CI = [1.28, 16.82], p = 0.02). CONCLUSIONS: Fixation of the peritoneum (PerFix) reduced the incidence of symptomatic lymphoceles in RARP with ePLND. We found no difference in the frequency of asymptomatic lymphocele development. The volume of the detected lymphoceles was similar. PATIENT SUMMARY: In this study, we compared the rate of development of postoperative complications using the peritoneal fixation technique with that of a nonfixation control group for robot-assisted radical prostatectomy with extended pelvic lymphadenectomy. Fixation of the peritoneum should obviate the development of severe complications in the postoperative period.

• MeSH
• lidé MeSH
• lymfadenektomie škodlivé účinky   metody   MeSH
• lymfokela * etiologie   prevence a kontrola   MeSH
• nádory prostaty * patologie   MeSH
• pánev patologie   MeSH
• peritoneum patologie   chirurgie   MeSH
• prospektivní studie MeSH
• prostatektomie škodlivé účinky   metody   MeSH
• retrospektivní studie MeSH
• roboticky asistované výkony * škodlivé účinky   metody   MeSH
• robotika * MeSH
• volné tkáňové laloky * patologie   MeSH
• Check Tag
• lidé MeSH
• mužské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• randomizované kontrolované studie MeSH

• MeSH
• dávka záření MeSH
• lidé MeSH
• nádory prostaty * epidemiologie   prevence a kontrola   terapie   MeSH
• prognóza MeSH
• prostatektomie metody   škodlivé účinky   MeSH
• radioterapie metody   škodlivé účinky   MeSH
• rizikové faktory MeSH
• sekundární prevence MeSH
• Check Tag
• lidé MeSH
• mužské pohlaví MeSH
• Publikační typ
• přehledy MeSH

Nefarmakologický způsob léčby erektilní dysfunkce využívá lineární aplikaci rázové vlny nízké intenzity. Tento způsob léčby je určen převážně pro nemocné s lehkou a středně těžkou vaskulogenní erektilní dysfunkcí. Míra pacientů, kteří uvádějí uspokojivé zlepšení, se pohybuje mezi 40-80 %. Výsledky studií ukazují, že léčba rázovou vlnou nízké intenzity by mohla zlepšit kvalitu erekce i u pacientů s těžkou poruchou erekce, kteří nereagují na tabletovou léčbu inhibitory fosfodiesterázy pátého typu nebo reagují nedostatečně, čímž se snižuje okamžitá potřeba invazivnější léčby. Efekt léčby se zdá být klinicky zřejmý počínaje 1-3 měsíci po ukončení léčby s následným progresivním poklesem erektilní funkce v průběhu času, ačkoli klinický efekt byl detekován i 5 let po léčbě. V poslední době byl také testován vliv rázové vlny v penilní rehabilitaci po radikální prostatektomii. Jsou nutné větší prospektivní randomizované, kontrolované studie a data z dlouhodobého sledování, aby lékaři získali větší důvěru, pokud jde o použití a účinnost rázové vlny u pacientů s erektilní dysfunkcí. Dalším cílem by mělo být definování léčebných protokolů, což může vést k větším klinickým přínosům.

A non-pharmacological method of treating erectile dysfunction uses the linear application of a low-intensity shock wave. This method of treatment is mainly indicated for patients with mild and moderate vasculogenic erectile dysfunction. The rate of patients reporting satisfactory improvement is between 40-80%. Study results show that low intensity shock wave therapy could improve erectile function even in patients with severe erectile dysfunction who are either unresponsive or insufficiently responsive to oral phosphodiesterase type 5 inhibitors, thereby reducing the immediate need for more invasive treatment. The effect of treatment appears to be clinically evident starting 1-3 months after the end of treatment, with a subsequent progressive decline of the achieved benefit in terms of erectile function over time, although some effects have been detected up to 5 years after treatment. Recently, the impact of shock waves has also been tested in penile rehabilitation after radical prostatectomy. Overall, larger prospective randomized controlled trials and long-term follow-up data are needed to give clinicians more confidence in the use and efficacy of shock wave therapy in patients with erectile dysfunction. Another goal should be to define treatment protocols that can lead to greater clinical benefits.

• MeSH
• erektilní dysfunkce * patofyziologie   terapie   MeSH
• léčba mimotělní rázovou vlnou * MeSH
• lidé středního věku MeSH
• lidé MeSH
• prostatektomie rehabilitace   škodlivé účinky   MeSH
• randomizované kontrolované studie jako téma MeSH
• Check Tag
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH

INTRODUCTION: The objective of this study was to investigate the effect and feasibility of linear low-intensity extracorporeal shockwave therapy (LI-LiESWT) as a penile rehabilitation method for erectile dysfunction (ED) after bilateral nerve-sparing (NS) radical prostatectomy (RP). METHODS: Patients who had undergone bilateral NS RP (either radical retropubic prostatectomy or robot-assisted laparoscopic RP), 3 or more months prior to the study, and who had no ED preoperatively and were suffering from mild to severe postoperative ED were included in the study. Four treatments were given over a 4-week period, using the PiezoWave2 device with a linear shockwave applicator and the linear shockwave tissue coverage (LSTC-ED®) technique. If the improvement in erectile function was still considered insufficient (less than an IIEF-5 score of 22-25) at 2 months after the start of LI-LiESWT, penile rehabilitation was supplemented by pharmacological penile rehabilitation. The final effect of treatment was evaluated after 12 months. The main outcome measure was changes in the five-item International Index of Erectile Function (IIEF-5) score. RESULTS: Between September 2019 and September 2020, a total of 40 patients were included in the study and randomly divided into 2 groups: treatment group and sham group. Eight patients were excluded from the study and were not evaluated due to other conditions which required additional treatment (COVID-19 disease, postoperative incontinence, urethral stricture, and ischemic stroke). Thirty-two patients were included in the final analysis: 16 in the control group and 16 in the intervention group. At 6 months from the end of treatment, patients in both the treatment and the sham group achieved physiological IIEF-5 values, and the beneficial effect persisted for 12 months after the end of treatment. CONCLUSIONS: LI-LiESWT using the LSTC-ED® technique is a suitable and safe method for penile rehabilitation in patients with ED after bilateral NS RP, not only because of the vasculogenic effect of LI-LiESWT but also because of its neuroprotective and/or regenerative effects.

• MeSH
• COVID-19 * MeSH
• erekce penisu MeSH
• erektilní dysfunkce * etiologie   terapie   MeSH
• léčba mimotělní rázovou vlnou * škodlivé účinky   MeSH
• lidé MeSH
• prostatektomie škodlivé účinky   metody   MeSH
• výsledek terapie MeSH
• Check Tag
• lidé MeSH
• mužské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• randomizované kontrolované studie MeSH

• MeSH
• hormonální substituční terapie metody   MeSH
• jednofotonová emisní výpočetní tomografie metody   MeSH
• lidé středního věku MeSH
• lidé MeSH
• magnetická rezonanční tomografie metody   MeSH
• metastázy nádorů farmakoterapie   MeSH
• nádory prostaty diagnóza   komplikace   terapie   MeSH
• PET/CT metody   MeSH
• prostatektomie metody   škodlivé účinky   MeSH
• prostatický specifický antigen krev   MeSH
• protokoly protinádorové léčby MeSH
• radioisotopová scintigrafie metody   MeSH
• radioterapie metody   MeSH
• senioři MeSH
• staging nádorů metody   MeSH
• výsledek terapie MeSH
• Check Tag
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• senioři MeSH
• Publikační typ
• kazuistiky MeSH

Úvod: Syndrom hyperaktivního měchýře po radikální prostatektomii je méně časté, ale závažné onemocnění, které může mít velký negativní dopad na kvalitu života.

Introduction: Hyperactive bladder syndrome after radical prostatectomy is a less common but serious disease that can have a major negative impact on quality of life. Method: A group of 500 patients after robot-assisted radical prostatectomy in 2016-2018 was evaluated. Hyperactive bladder was assessed on the basis of micturition diaries 3 and 6 months after surgery. Results: The median follow-up was 36 months. Overactive bladder syndrome was diagnosed in 15 (3 %) patients. First-generation anticholinergic therapy was effective in 12 (80 %) patients. In three (20 %) patients, treatment was changed to solifenacin, which remained effective. After 6 months, the treatment was effective and did not need to be changed in the long term, Conclusion: The incidence of overactive bladder syndrome was low in our cohort (3 %), which was less than in similar published studies. In most patients (80 %), first-generation anticholinergic therapy was effective. If the therapeutic effect was insufficient or side effects occurred, treatment with solifenacin was effective.

• MeSH
• cholinergní antagonisté farmakologie   terapeutické užití   MeSH
• hyperaktivní močový měchýř * etiologie   farmakoterapie   MeSH
• lidé MeSH
• pooperační komplikace MeSH
• prostatektomie škodlivé účinky   MeSH
• retrospektivní studie MeSH
• Check Tag
• lidé MeSH
• mužské pohlaví MeSH

Radikální prostatektomie (RP) s rozšířenou pánevní lymfadenektomií (ePLND) představuje standardní terapii středně a vysoce rizikového lokalizovaného karcinomu prostaty (PCa). Využití ePLND v poslední době narůstá díky provádění většího množství RP u agresivnějších nádorů. Jednou z častých komplikací této operace je vznik symptomatických lymfokél, který se udává až u 10 % operovaných. Dosud, i přes rozsáhlý výzkum, nebyla nalezena vhodná strategie, jak předejít této komplikaci. Jednou z potenciálně úspěšných intervencí se zdá být fixace volného listu peritonea při provádění transperitoneální RP. Několik retrospektivních klinických studií prokázalo snížení výskytu symptomatických lymfokél při fixování peritonea k měchýři nebo stěně pánve, čímž je ponechána mezera v peritoneu, která vytvoří cestu pro volný pohyb lymfy z pánevní oblasti do peritoneální dutiny a její následnou resorpci. Jediná dosud publikovaná randomizovaná studie však tuto hypotézu nepotvrdila. Cílem tohoto článku je představit přehled dosud publikovaných klinických studií zabývajících se fixací peritonea.

Radical prostatectomy (RP) with extended pelvic lymph node dissection (ePLND) is currently a standard of care of intermediate and high-risk localized prostate cancer (PCa). The utilization of ePLND is increasing due to stage migration towards more aggressive cancer. Symptomatic lymphoceles, with incidence ranging up to 10 %, are one of the most frequent complications of ePLND. No successful strategy on how to prevent their occurrence has been found so far. One of the promising interventions could be peritoneal flap fixation during transperitoneal RP. Several retrospective studies have shown a reduction in the incidence of symptomatic lymphocele. The peritoneum can be fixed to the urinary bladder or to the pelvic wall leaving a window in the peritoneum that presents a pathway that directs the lymphatic fluid out of the pelvis into the peritoneal cavity where it can be absorbed. The only randomized trial published so far, however, did not show any benefit. This article aims to present an overview of published clinical studies on the fixation of the peritoneum.

• Klíčová slova
• fixace peritonea,
• MeSH
• lidé MeSH
• lymfadenektomie * metody   škodlivé účinky   MeSH
• lymfokela * etiologie   prevence a kontrola   MeSH
• nádory prostaty chirurgie   MeSH
• prostatektomie metody   škodlivé účinky   MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• práce podpořená grantem MeSH
• přehledy MeSH

BACKGROUND: To analyze postoperative, in-hospital, complication rates in patients with organ transplantation before radical prostatectomy (RP). METHODS: From National Inpatient Sample (NIS) database (2000-2015) prostate cancer patients treated with RP were abstracted and stratified according to prior organ transplant versus nontransplant. Multivariable logistic regression models predicted in-hospital complications. RESULTS: Of all eligible 202,419 RP patients, 216 (0.1%) underwent RP after prior organ transplantation. Transplant RP patients exhibited higher proportions of Charlson comorbidity index ≥2 (13.0% vs. 3.0%), obesity (9.3% vs. 5.6%, both p < 0.05), versus to nontransplant RP. Of transplant RP patients, 96 underwent kidney (44.4%), 44 heart (20.4%), 40 liver (18.5%), 30 (13.9%) bone marrow, <11 lung (<5%), and <11 pancreatic (<5%) transplantation before RP. Within transplant RP patients, rates of lymph node dissection ranged from 37.5% (kidney transplant) to 60.0% (bone marrow transplant, p < 0.01) versus 51% in nontransplant patients. Regarding in-hospital complications, transplant patients more frequently exhibited, diabetic (31.5% vs. 11.6%, p < 0.001), major (7.9% vs. 2.9%) cardiac complications (3.2% vs. 1.2%, p = 0.01), and acute kidney failure (5.1% vs. 0.9%, p < 0.001), versus nontransplant RP. In multivariable logistic regression models, transplant RP patients were at higher risk of acute kidney failure (odds ratio [OR]: 4.83), diabetic (OR: 2.81), major (OR: 2.39), intraoperative (OR: 2.38), cardiac (OR: 2.16), transfusion (OR: 1.37), and overall complications (1.36, all p < 0.001). No in-hospital mortalities were recorded in transplant patients after RP. CONCLUSIONS: Of all transplants before RP, kidney ranks first. RP patients with prior transplantation have an increased risk of in-hospital complications. The highest risk, relative to nontransplant RP patients appears to acute kidney failure.

• MeSH
• akutní poškození ledvin * epidemiologie   etiologie   terapie   MeSH
• databáze faktografické MeSH
• hodnocení rizik statistika a číselné údaje   MeSH
• hospitalizace statistika a číselné údaje   MeSH
• komorbidita MeSH
• lidé středního věku MeSH
• lidé MeSH
• nádory prostaty * epidemiologie   patologie   chirurgie   MeSH
• pooperační komplikace * diagnóza   epidemiologie   terapie   MeSH
• prostatektomie škodlivé účinky   metody   statistika a číselné údaje   MeSH
• rizikové faktory MeSH
• transplantace ledvin statistika a číselné údaje   MeSH
• transplantace orgánů * klasifikace   statistika a číselné údaje   MeSH
• transplantace srdce statistika a číselné údaje   MeSH
• Check Tag
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• Geografické názvy
• Německo MeSH